NXL
Nexalin Technology, Inc. (NXL) is rated C- (2.1/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Value (B-); its weakest is Momentum (F). The rating has held at C- for 5 weeks.
Quantitative Factor Evaluation • Updated
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-13 | B- (3.0) | C (2.5) | C- (2.1) | F (0.4) | C+ (2.6) | C- (2.1) |
| 2026-11-06 | B- (3.0) | C (2.5) | C (2.2) | F (0.5) | C+ (2.7) | C- (2.1) |
| 2026-10-30 | B- (3.0) | C (2.4) | C (2.2) | F (0.5) | C+ (2.7) | C- (2.1) |
| 2026-10-23 | B- (3.0) | C (2.4) | C- (2.1) | F (0.4) | C+ (2.6) | C- (2.1) |
| 2026-10-16 | B- (3.0) | C (2.4) | C- (2.1) | F (0.4) | C+ (2.6) | C- (2.1) |